United States

People: Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

4:57am EDT
Change (% chg)

kr.-2.95 (-0.85%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gregoire, Sylvie 

Dr. Sylvie L. Gregoire, Ph.D. has been Independent Director at Novo Nordisk A/S since March 19, 2015. She has also been Member of the Audit Committee since 2015 and serves as Member of the Research & Development Committee since 2017 and Member of the Nomination Committee since March 22, 2018. She was previously President of Human Genetic Therapies, Shire plc, US and Switzerland, from 2007 to 2013. She is Member of the boards of Vifor Pharma Ltd. and Perkin Elmer Inc., as well as Chairman of Corvidia Therapeutics Inc. and Executive Chair of the Board of EIP Pharma, Inc. She has knowledge of the regulatory environment in both the US and the EU, having experience of all phases of the product life cycle, including discovery, registration, pre-launch and managing the life cycle while on the market. In addition, she has financial insight from i.a. P&L responsibility. She holds Pharmacy Doctorate degree (1986) from the State University of NY at Buffalo, US, BA in Pharmacy (1984) from Laval University, Canada, and Science College degree (1980) from Seminaire de Sherbrooke, Canada.

Basic Compensation

Total Annual Compensation, DKK 1,600,000
Restricted Stock Awards, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 1,600,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --